ARIAD Pharmaceuticals, Inc. (ARIA) had an volatile session and gained 0.01 points till last call. The price was at $23.83, gaining 0.02% till the last intraday data. The total uptick value was $4.94 million while the total downtick value was $9.83 million. The shares saw a net money flow of $(-4.89) million and the up/down ratio stood at 0.5. The stock has seen a change of of 0.61% for the week. The share had a block transaction during the course of trading in which the net money flow was $(-3.94) million. Almost $0 million were received in upticks and approximately $3.94 million were lost in downticks, thereby giving the up/down ratio of 0.Block trades are executed by Investment Banking firms or Wealth Managers shifting positions or Day traders taking advantage of trading signals.
Shares of ARIAD Pharmaceuticals, Inc. rose by 0.3% in the last five trading days and 91.24% for the last 4 weeks. ARIAD Pharmaceuticals, Inc. is up 172.82% in the last 3-month period. Year-to-Date the stock performance stands at 91.24%. ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) witnessed a decline in the market cap on Wednesday as its shares dropped 0.13% or 0.03 points. After the session commenced at $23.81, the stock reached the higher end at $23.84 while it hit a low of $23.74. With the volume soaring to 11,893,755 shares, the last trade was called at $23.79. The company has a 52-week high of $23.85. The company has a market cap of $4,620 million and there are 194,200,860 shares in outstanding. The 52-week low of the share price is $4.37.
Company has reported several Insider transactions to the SEC, on Jan 10, 2017, Daniel M Bollag (Sr. VP, Reg. Affairs & Quality) sold 32,000 shares at 23.78 per share price.On Sep 28, 2016, Timothy P Clackson (President, R&D, CSO) sold 8,750 shares at 13.98 per share price.On Jun 29, 2016, Hugh M Cole (SVP, Chief Business Officer) sold 6,012 shares at 7.05 per share price.
Ariad Pharmaceuticals Last issued its quarterly earnings results on Nov 7, 2016. The company reported $-0.12 EPS for the quarter, beating the analyst consensus estimate by $ 0.06. Analyst had a consensus of $-0.18. The company had revenue of $46.02 million for the quarter, compared to analysts expectations of $42.80 million. The companys revenue was up 58.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.29 EPS.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Ariad Pharmaceuticals was Downgraded by SunTrust to Hold on Jan 11, 2017. Ariad Pharmaceuticals was Downgraded by Jefferies to Hold on Jan 10, 2017. Company shares were Upgraded by Barclays on Jan 10, 2017 to Equal Weight, Raises Price Target to $ 24 from a previous price target of $9 .Ariad Pharmaceuticals was Downgraded by Leerink Partners to Mkt Perform on Jan 10, 2017.
Ariad Pharmaceuticals is engaged in the discovery and development of novel pharmaceuticals based on intracellular signaling technology. The Company has established highly integrated capabilities in functional genomics, molecular cell biology, structure based drug design, combinatorial chemistry and pharmacology. The company is developing small-molecule drugs that block signal transduction pathways in cells responsible for osteoporosis, and immune and inflammatory diseases.